BioCryst Pharmaceuticals Inc (BCRX): Revenue
$874.84M
Year ended 2025-12-31
$940.61M
Trailing 12 months to 2026-06-30
+47.8%
3-year compound annual growth
+117.9%
5-year compound annual growth
+33.6%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $874.84M | +94.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $450.71M | +36.0% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $331.41M | +22.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $270.83M | +72.3% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $157.17M | +782.4% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $17.81M | -63.5% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $48.84M | +136.5% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $20.65M | -18.0% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $25.19M | -4.4% | 2020-03-13, From 2017-01-01 |
| 2016-12-31 | $26.35M | -45.4% | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | $48.26M | +254.6% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $13.61M | -21.5% | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | $17.33M | -34.1% | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | $26.29M | +33.9% | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | $19.64M | -68.5% | 2014-03-10, From 2011-01-01 |
| 2010-12-31 | $62.38M | -16.4% | 2013-03-11, From 2010-01-01 |
| 2009-12-31 | $74.59M | n/a | 2012-03-06, From 2009-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $874.84M | +94.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $738.26M | +16.4% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.12B | +64.7% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $1.22B | -0.4% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $1.40B | +37.6% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $510.17M | +19.6% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $451.36M | +146.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $400.02M | +29.0% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $1.94B | -39.9% |
Compare BCRX, RGEN, NVAX, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗